Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their experience with hair recovery after a second shedding phase while using Finasteride. They advise staying consistent with treatment, as it can take 1-2 years or more to see results, and also mention using Ketoconazole but are unsure of its effectiveness.

The post discusses an individual's 11-month hair restoration journey using oral finasteride, topical minoxidil and finasteride, micro-needling, biotin tablets, and ketoconazole shampoo. Despite mixed reactions and skepticism from others, the individual expresses gratitude for support and claims progress in hair growth.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

The conversation discusses a user's two-year hair regrowth progress using finasteride, minoxidil, and microneedling. One user asks for a timeline of progress, another comments on hair length, and the original poster mentions using microneedling sporadically.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A 33-year-old female with androgenic alopecia experienced alopecia areata patches after PRP treatment. She is seeking others' experiences with PRP worsening alopecia areata.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

Hair regrowth after 13 weeks using topical minoxidil, oral finasteride, peptide shampoo, serum, and a red light hat. Some growth is attributed to a recent hair transplant.

The user has been using 1mg Finasteride and 5% topical Minoxidil for 9 months with little improvement and is now switching to 5mg oral Minoxidil, continuing microneedling, and adding Anagenil Complex. They are seeking advice on whether to stop topical Minoxidil and the effectiveness of Anagenil Complex.

The user experienced significant hair regrowth after 7 months using oral finasteride, minoxidil, and microneedling. They are considering dutasteride but plan to continue with finasteride for a year before making changes.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

The user has been using oral finasteride and minoxidil nightly, dutasteride twice a week, microneedling weekly, and pyripure nightly since April. They are seeking opinions on their hair regrowth progress, noting no slick bald areas but some miniaturized blonde hairs.

Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.

A 33-year-old experienced significant hair regrowth on the crown after one year of using oral finasteride (1mg) and minoxidil (2.5mg) daily, with initial concerns about libido that resolved after a week. The user reported minimal shedding and no other side effects, making a hair transplant optional.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

The user is using finasteride, topical minoxidil, derma rolling, ketoconazole shampoo, and multivitamins for hair regrowth. They also drink topical minoxidil due to the unavailability of oral minoxidil, despite concerns from others about safety.

The user is experiencing positive hair regrowth results after four months of using oral finasteride (1mg daily), oral minoxidil (5mg daily), Polaris NR02 shampoo, and ketoconazole 2% shampoo. They plan to continue the regimen and consider a hair transplant in the future, with no reported side effects from the current treatment.

Hair cloning trials by Stempsen Therapeutics and Hairclone have no updates, and it may take at least 15 years for hair cloning to be available. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.